Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study.
1. The reproducibility of angiotensin converting enzyme inhibitor induced cough was examined in a double-blind cross over study in patients previously shown to have exhibited this side effect. 2. Ninety-seven patients who had experienced angiotensin converting enzyme inhibitor cough within the last 2 years were challenged with enalapril 20 mg daily for 4 weeks to establish eligibility. Eighty-eight of 97 (91%) patients experienced a repeat of their cough symptoms. Sixty-four patients entered the double-blind part of the study where they were treated with enalapril 20 mg and a renin inhibitor for up to 4 weeks in random order. These periods were separated by a minimum 4 week placebo wash out. 3. Of 59 evaluable patients who received enalapril a second time, 37 (62.7%) experienced cough again. Of 62 patients on the renin inhibitor 16 (25.8%) experienced cough, however as it was not equi-efficacious to enalapril no valid comparison could be made. 4. Angiotensin converting enzyme inhibitor cough is not reproducible within patients, as other factors are involved in the aetiology. Objective testing with blinded assessment together with symptom reporting, would give a more accurate measure of the incidence, and mechanism of this side effect.
Charlon
V
V
Roche Products Limited, Maidenhead, Berks.
Dollow
S
S
Fidel
J
J
Hoglund
C
C
Honkanen
T
T
Kobrin
I
I
McEwan
J
J
McInnes
G
G
Viskoper
J R
JR
Woo
K S
KS
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D003371:Cough / Q000139:chemically induced*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004656:Enalapril / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D000092502:Renin Inhibitors
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D000092502:Renin Inhibitors